Schmidt R, Al Zaki A, Desilet N, et al. - Between 2013 and 2015, researchers examined health records from consecutive individuals referred to the institution for cancer-associated VTE management to explain their clinical course and outcomes from 6 to 24 months following their index venous thromboembolism (VTE). Details on individual and cancer characteristics, objectively documented recurrent venous thromboembolism (rVTE), clinically relevant bleeding (CRB) and overall mortality were obtained. A total of 524 individuals were included and 322 were alive at 6 months after the index VTE. The results of this study indicated that individuals with cancer-associated VTE who are alive at 6 months after VTE diagnosis remains at high risk of rVTE, CRB and death.